ACCELERATE: Evacetrapib’s clinical failure sinks lipid-drug class
April 20, 2016|Cardiology News
Author and Disclosure Information
AT ACC 2016
A pivotal trial for a fourth new drug from the class of cholesterol ester transfer protein inhibitors is in progress, the REVEAL study, using the drug anacetrapib. More than 30,000 patients have been enrolled, and a report on the results should be available in 2017.
Dr. Nicholls and Dr. Nissen disclosed ties with several drug companies including Eli Lilly, which sponsored the trial and is developing evacetrapib. Dr. Masoudi had no disclosures.
On Twitter @mitchelzoler
